Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on October 11, 2023
September 19 2023 - 7:30AM
Business Wire
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases, today announced
that it will host an Investor & Analyst Event focused on the
Developmental and Epileptic Encephalopathy (DEE) landscape and
LP352, a first-in-class 5-HT2C receptor superagonist in development
for the potential treatment of seizures associated with DEEs.
The event will feature DEE thought leaders who will discuss the
unmet medical need and current and emerging treatment landscape for
people living with refractory epilepsies.
The Longboard Pharmaceuticals team will discuss the opportunity
within the DEE landscape and the ongoing Phase 1b/2a PACIFIC Study
evaluating LP352 as a potential treatment of seizures associated
with a broad range of DEEs. The PACIFIC Study is fully enrolled,
and topline data are expected around year-end 2023.
A live question and answer session will follow the formal
presentations.
EVENT DETAILS: WHEN: Wednesday, October 11, 2023 |
9:30 – 11:30 AM ET WHERE: Cooley LLP, 55 Hudson Yards, New
York, NY 10001 REGISTRATION LINK (both in-person and
virtual*): https://lifescievents.com/event/longboard/
*In-person attendance is limited to invited research analysts
and institutional investors only. All other guests are invited to
view the live or archived webcast virtually on the Investor
Relations section of Longboard’s website at
https://www.longboardpharma.com/. The archived webcast will be
available for at least 30 days following the event.
ABOUT LP352
LP352 is an oral, centrally acting, 5-HT2C superagonist in
development for the potential treatment of seizures associated with
DEEs such as Lennox-Gastaut syndrome, Dravet syndrome,
SCN2A-related epilepsies, CDKL5 deficiency disorder, and other
epileptic disorders. LP352 is designed to modulate GABA and, as a
result, suppress the central hyperexcitability that is
characteristic of seizures. LP352 has novel chemistry and
attributes, and was designed to be highly specific and selective
for the 5-HT2C receptor subtype, giving it the potential to reduce
seizures in patients with DEEs while overcoming the known or
perceived safety limitations of available drugs in the 5-HT2 class.
LP352 is currently being evaluated in a Phase 1b/2a clinical trial
(the PACIFIC Study) in participants with DEEs, with topline data
expected around year-end 2023, as well as in additional supportive
studies.
ABOUT THE PACIFIC STUDY
The PACIFIC Study is a Phase 1b/2a clinical trial evaluating
participants with DEEs. The primary objectives of the study are to
assess the safety and tolerability of LP352. The PACIFIC Study will
also evaluate change in seizure frequency over the treatment
period. The study enrolled 52 participants with a variety of
treatment resistant seizures that fall into the category of DEE
across approximately 30 study sites in the United States and
Australia. The PACIFIC Study data are expected to inform the design
and characteristics of the planned Phase 3 program for LP352.
Participants who complete the PACIFIC Study are eligible to roll
over into the ongoing open-label extension (OLE) trial should they
choose to do so. The OLE is a Phase 2 multicenter, open-label,
multiple-dose, long-term extension clinical trial designed to
evaluate long-term safety of LP352 in participants with DEEs who
have completed the PACIFIC Study.
ABOUT LONGBOARD PHARMACEUTICALS
Longboard Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases. Longboard is
working to advance a portfolio of centrally acting product
candidates designed to be highly selective for specific G
protein-coupled receptors (GPCRs). Longboard’s small molecule
product candidates are based on more than 20 years of GPCR
research. Longboard is evaluating LP352, an oral, centrally acting
5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no
detectable activity on 5-HT2B and 5-HT2A receptor subtypes, in
development for the potential treatment of seizures associated with
a broad range of Developmental and Epileptic Encephalopathies.
Longboard is also evaluating LP659, an oral, centrally acting,
sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator,
which is in development for the potential treatment of multiple
neurological diseases.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. In
some cases, you can identify forward-looking statements by words
such as “will”, “potential”, “emerging”, “opportunity”, “expected”,
“designed to”, “focused on”, “working to”, or the negative, plural
or other tenses of these words or other comparable language, and
they include, without limitation, statements about the following:
Longboard’s participation in the upcoming Investor & Analyst
Event; anticipated timing of topline data for the PACIFIC Study;
LP352, including its potential to treat seizures associated with a
broad range of DEEs, its potential to reduce seizures in patients
with DEEs while overcoming the known or perceived safety
limitations of available drugs in the 5-HT2 class, and its
selectivity, design, chemistry, and attributes; the opportunity
within the DEE landscape; and Longboard’s clinical and preclinical
programs and product candidates, ability to develop product
candidates and deliver medicines, and focus. For such statements,
Longboard claims the protection of the Private Securities
Litigation Reform Act of 1995. Actual events or results may differ
materially from Longboard’s expectations. Factors that could cause
actual results to differ materially from those stated or implied by
Longboard’s forward-looking statements include, but are not limited
to, the following: Longboard’s product candidates, including LP352,
are in the early to middle stages of a lengthy research,
development, and regulatory review process, the timing, manner and
outcome of which is uncertain, and Longboard’s product candidates
may not advance in research or development or be approved for
marketing; nonclinical and clinical data is voluminous and
detailed, and regulatory agencies may interpret or weigh the
importance of data differently and reach different conclusions than
Longboard or others, request additional information, have
additional recommendations or change their guidance or requirements
before or after approval; results of clinical trials and other
studies are subject to different interpretations and may not be
predictive of future results; topline data may not accurately
reflect the complete results of a particular study or trial;
enrolling participants in Longboard’s ongoing and intended clinical
trials is competitive and challenging; other risks related to the
development and commercialization of Longboard’s product
candidates; risks related to Longboard’s limited operating history,
financial position and need for additional capital; Longboard will
need additional managerial and financial resources to advance all
of its programs, and you and others may not agree with the manner
Longboard allocates its resources; macroeconomic events stemming
from the COVID-19 pandemic or evolving geopolitical developments
such as the conflict in Ukraine, including but not limited to the
impact on Longboard’s clinical trials and operations, the
operations of Longboard’s suppliers, partners, collaborators, and
licensees, and capital markets, which in each case remains
uncertain; risks related to unexpected or unfavorable new data;
risks related to relying on licenses or collaborative arrangements;
other risks related to Longboard’s dependence on third parties;
competition; product liability or other litigation or disagreements
with others; government and third-party payor actions, including
relating to reimbursement and pricing; risks related to regulatory
compliance; and risks related to Longboard’s and third parties’
intellectual property rights. Additional factors that could cause
actual results to differ materially from those stated or implied by
Longboard’s forward-looking statements are disclosed in Longboard’s
filings with the Securities and Exchange Commission (SEC). These
forward-looking statements represent Longboard’s judgment as of the
time of this release. Longboard disclaims any intent or obligation
to update these forward-looking statements, other than as may be
required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230919467748/en/
CORPORATE CONTACT: Megan E. Knight Head of Investor
Relations IR@longboardpharma.com 858.789.9283
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jul 2023 to Jul 2024